Merck (MRK) Reports In-Line Q4; Guides In-Line

Merck (NYSE: MRK) reported Q4 EPS of $0.89, versus the consensus of $0.89. Revenue for the quarter came in at $10.1 billion, versus $10.22 billion consensus.

GUIDANCE:

Merck sees FY2017 EPS of $3.72-$3.87, versus the consensus of $3.85.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c